RegeneRx Biopharmaceuticals (RGRX) News Today → My top 100 stocks… (From DTI) (Ad) Free RGRX Stock Alerts $0.0014 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineReviewing RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) and GH Research (NASDAQ:GHRS)americanbankingnews.com - April 24 at 1:48 AMRegenerx Biopharmaceuticals Inc RGRXDmorningstar.com - November 5 at 8:42 AMRegenerx Biopharm In (RGRXD)investing.com - October 31 at 12:56 AMLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater Chinabusinesswire.com - September 21 at 7:56 AMRGRX RegeneRx Biopharmaceuticals, Inc.seekingalpha.com - August 26 at 5:53 AMRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligationsfinance.yahoo.com - August 15 at 1:45 PMRegeneRx Receives Stockholder Approval for Reverse Stock Splitfinance.yahoo.com - August 8 at 10:30 AMRegeneRx To Extend Consent Solicitation Votefinance.yahoo.com - August 1 at 8:11 PMBristol-Myers to Split Off Mead Johnsonthestreet.com - July 7 at 12:14 AMPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage Initiationthestreet.com - May 19 at 7:27 AMFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259finance.yahoo.com - April 13 at 12:49 PMBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030marketwatch.com - April 7 at 8:50 PMBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029marketwatch.com - April 7 at 8:50 PM2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029marketwatch.com - March 1 at 9:02 PMBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028marketwatch.com - February 25 at 5:33 PMBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027marketwatch.com - February 24 at 10:26 AMBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)finance.yahoo.com - February 12 at 3:46 PMThymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapyfinance.yahoo.com - January 31 at 10:19 AM$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buyingmarkets.businessinsider.com - January 27 at 12:45 AMBiopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]marketwatch.com - January 18 at 2:53 PMBiopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the Reportmarketwatch.com - January 17 at 2:18 PMPublication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathyfinance.yahoo.com - January 3 at 8:56 AMBiopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic Partnershipsfinance.yahoo.com - November 18 at 11:40 PMRegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Diseasefinance.yahoo.com - October 24 at 2:02 PMClover Biopharmaceuticals Ltd (2197)investing.com - September 30 at 1:59 PMRegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)finance.yahoo.com - September 27 at 1:12 PMRegeneRx Issues 2022 Letter To Stockholdersfinance.yahoo.com - August 22 at 11:56 AMRegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitisfinance.yahoo.com - July 18 at 11:18 AMRegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259finance.yahoo.com - June 22 at 4:52 PMTβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Corneafinance.yahoo.com - May 4 at 2:51 PMRegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Healthfinance.yahoo.com - February 11 at 10:14 AMRGRX Real-Time Quotesnasdaq.com - February 7 at 10:20 PMResearchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injuryfinance.yahoo.com - January 25 at 9:48 AMRGRX After-Hours Quotesnasdaq.com - January 20 at 6:33 PMMicrocap RegeneRx surges 17% on regulatory development for ophthalmic candidateseekingalpha.com - January 12 at 5:21 PMRegeneRx Publishes Regulatory Update on RGN-259stockhouse.com - January 12 at 12:21 PMRegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022finance.yahoo.com - December 17 at 12:10 PMRegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndromefinance.yahoo.com - November 29 at 12:50 PMClinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meetingfinance.yahoo.com - October 29 at 12:53 PMResearchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsisfinance.yahoo.com - October 6 at 11:00 AMNew Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Diseasefinance.yahoo.com - October 5 at 9:24 AMBeyond Meat's plant-based 'chicken' tenders are coming to grocery storesyahoo.com - September 30 at 12:19 AMRegeneRx Licensee Acquired by Korean Biopharmaceutical Groupfinance.yahoo.com - September 27 at 11:28 AMRegenerx Biopharmaceuticals Inc RGRXmorningstar.com - July 25 at 12:40 AMRegeneRx Issues Letter To Stockholdersfinance.yahoo.com - July 22 at 10:23 AM Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address If you have $2,500 bucks… check this out (Ad)This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. RGRX Media Mentions By Week RGRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGRX News Sentiment▼0.000.33▲Average Medical News Sentiment RGRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGRX Articles This Week▼10▲RGRX Articles Average Week Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sienna Biopharmaceuticals News IMV News Kaleido Biosciences News Bayer Aktiengesellschaft News Capstone News Context Therapeutics News EOM Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RGRX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RegeneRx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
